Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study [PDF]
Drugs - Real World OutcomesBackground Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are an effective preventive treatment for migraine. However, their population-level utilization patterns and treatment gaps are underreported in Japan.
Yoshiki Hanaoka +9 more
doaj +2 more sources
Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches [PDF]
Medeniyet Medical JournalThis review aimed to summarize current evidence on the diagnostic criteria, pathophysiological mechanisms, differential diagnosis, and treatment approaches of vestibular migraine.
Ülkü Figen DEMIR +1 more
doaj +2 more sources
Клинический разбор в общей медицине, 2023 Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment.
Anna V. Berdnikova +4 more
doaj +1 more source
Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
Saudi Journal of Medicine and Medical Sciences, 2023 Migraine is a potentially disabling disorder, yet it remains underdiagnosed and undertreated. The release of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigemino-cerebrovascular system plays a vital role in the evolution of migraine ...
Suruchi Aditya, Aditya Rattan
doaj +1 more source
Serum calcitonin gene related peptide (CGRP) levels in migraine: A study on its clinical correlation and diagnostic efficacy [PDF]
Romanian Journal of Neurology, 2021 Migraine is a primary headache disorder marked by recurrent unilateral headache episodes. Calcitonin gene related peptide (CGRP) plays major role in migraine pathophysiology.
Sofia Khatoon +7 more
doaj +1 more source
The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody [PDF]
Анналы клинической и экспериментальной неврологии, 2023 Introduction. High prevalence of migraine and its impact on quality of life requires the development of original agents. In 2020, fremanezumab, a new calcitonin gene-related peptide monoclonal antibody was authorized in Russia.
Larisa A. Dobrynina +4 more
doaj +1 more source
New strategies for migraine treatment and prevention
Aktualności Neurologiczne, 2019 Migraine is a neurological disorder characterised by recurrent attacks of headache accompanied by vegetative symptoms. It is estimated that 11–12% of the world’s population suffers from migraine.
Waldemar Brola, Piotr Sobolewski
doaj +1 more source
Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine
Medicine, 2022 . Menstrual migraine (MM) has a longer duration and higher drug resistance than non-perimenstrual migraine. Calcitonin gene-related peptide (CGRP) and CGRP receptors are expressed in the peripheral and central nervous systems throughout the ...
Yan Jiang, MMed, Zhen-Lun Huang, BMed
doaj +1 more source
The Journal of Headache and Pain, 2022 Background The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients.
Sanne Hage La Cour +6 more
doaj +1 more source
Медицинский совет, 2022 Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both ...
N. V. Vashchenko +5 more
doaj +1 more source